This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and ...
New research presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following ...
The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player ...
Scientists developed a five-target obesity drug that outperformed Ozempic in weight loss and blood sugar control in obese ...
Researchers have created a next-generation obesity drug that works like a “Trojan horse,” using GLP-1/GIP signals to slip a ...
Vietnam Investment Review on MSN
Harbour BioMed announces promising preclinical data for its first ai enabled drug candidate
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and ...
A new systematic review and meta-analysis of studies presented at the European Congress on Obesity in Istanbul, Turkey (May ...
Millions of older Americans may have access for the first time to obesity drugs at a low price of $50 a month starting in ...
Pharma stocks are gaining momentum as obesity drugs, oncology therapies and biotech innovation boost investor optimism.
Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction ...
Adding a dual GLP-1/GIP receptor agonist to the psoriasis drug ixekizumab (Taltz) significantly improved outcomes in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results